Pegfilgrastim Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The Business Research Company’s Pegfilgrastim Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, April 26, 2022 /EINPresswire.com/ -- Companies in the global pegfilgrastim biosimilars market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in April 2020, Biocon, an India based biopharmaceutical company partnered with Mylan, a US based generic and specialty pharmaceuticals company to introduce Fulphila, biosimilar pegfilgrastim in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy in order to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

The global pegfilgrastim biosimilars market size is expected to grow from $1.17 billion in 2021 to $1.28 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market share is expected to reach $1.92 billion in 2026 at a CAGR of 10.6%.

Read more on the Global Pegfilgrastim Biosimilars Market Report
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market growth. Governments worldwide are focusing on the development of biosimilars attributing to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aids in the increased production and awareness which in turn supported the growth of the pegfilgrastim biosimilars market.

North America was the largest region in the pegfilgrastim biosimilars market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Major players covered in the global pegfilgrastim biosimilars industry are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.

TBRC’s global pegfilgrastim biosimilars market report is segmented by application into chemotherapy treatment, transplantation, others, by distribution channel into hospital pharmacies, retail pharmacies, mail-order pharmacies.

Pegfilgrastim Biosimilars Global Market Report 2022 – By Application (Chemotherapy Treatment, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a pegfilgrastim biosimilars market overview, forecast pegfilgrastim biosimilars market size and growth for the whole market, pegfilgrastim biosimilars market segments, geographies, pegfilgrastim biosimilars market trends, pegfilgrastim biosimilars market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request for a Sample of the Global Pegfilgrastim Biosimilars Market Report
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Organization) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 – By Product (Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)), By Application (Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.